hydroxychloroquine has been researched along with Chronic Kidney Diseases in 18 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine is widely used in patients with rheumatoid arthritis." | 7.88 | Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis. ( Chang, CC; Chiu, PF; Hsu, CC; Kor, CT; Tarng, DC; Wu, CL; Yang, TH, 2018) |
| " Hydroxychloroquine (HCQ), an anti-inflammatory drug, has been shown to have multiple pleiotropic actions relevant to atherosclerosis." | 7.81 | Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease. ( Apostolov, EO; Bose, C; Fahmi, T; Karaduta, OK; Kaushal, GP; Segal, MS; Shah, SV; Shukla, AM, 2015) |
| "Hydroxychloroquine (HCQ) has been adapted for the treatment of autoimmune diseases; however, the potential mechanism underlying the role of HCQ in renal fibrosis remains unclear." | 5.72 | Hydroxychloroquine alleviates renal interstitial fibrosis by inhibiting the PI3K/Akt signaling pathway. ( Bai, F; Fan, J; Feng, F; Li, D; Liu, L; Sun, N; Yang, H; Yang, X; Yu, K; Zhang, Y, 2022) |
| "Hydroxychloroquine is widely used in patients with rheumatoid arthritis." | 3.88 | Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis. ( Chang, CC; Chiu, PF; Hsu, CC; Kor, CT; Tarng, DC; Wu, CL; Yang, TH, 2018) |
| " Hydroxychloroquine (HCQ), an anti-inflammatory drug, has been shown to have multiple pleiotropic actions relevant to atherosclerosis." | 3.81 | Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease. ( Apostolov, EO; Bose, C; Fahmi, T; Karaduta, OK; Kaushal, GP; Segal, MS; Shah, SV; Shukla, AM, 2015) |
| " This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD." | 2.66 | Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. ( Govil, A; Luckett, K; Miller-Handley, H, 2020) |
| "To compare the 90-day risk of serious adverse events among adults with CKD who started low-dose methotrexate vs those who started hydroxychloroquine and to compare the risk of serious adverse events among adults with CKD starting 2 distinct doses of methotrexate vs those starting hydroxychloroquine." | 1.91 | Low-Dose Methotrexate and Serious Adverse Events Among Older Adults With Chronic Kidney Disease. ( Ahmadi, F; Blake, PG; Garg, AX; Kim, RB; McArthur, E; Muanda, FT; Sontrop, JM; Urquhart, BL; Weir, MA, 2023) |
| "Hydroxychloroquine (HCQ) has been adapted for the treatment of autoimmune diseases; however, the potential mechanism underlying the role of HCQ in renal fibrosis remains unclear." | 1.72 | Hydroxychloroquine alleviates renal interstitial fibrosis by inhibiting the PI3K/Akt signaling pathway. ( Bai, F; Fan, J; Feng, F; Li, D; Liu, L; Sun, N; Yang, H; Yang, X; Yu, K; Zhang, Y, 2022) |
| "Prognosis of lupus nephritis (LN) among patients of African descent living in Europe has been understudied." | 1.72 | Worse long-term renal outcome of lupus nephritis patients of African descent living in Europe. ( Costedoat-Chalumeau, N; Enfrein, A; Houssiau, F; Karras, A; Le Guern, V; Pirson, V; Tamirou, F, 2022) |
| "There is little information about Coronavirus Disease 2019 (COVID-19) in children with underlying chronic renal pathologies." | 1.56 | SARS-CoV-2 infection in Spanish children with chronic kidney pathologies. ( Alvárez, O; Lumbreras, J; Madrid, A; Melgosa, M; Nieto, F; Parada, E; Perez-Beltrán, V, 2020) |
| "Hydroxychloroquine (HCQ) has been promoted as a potential treatment of coronavirus disease 2019 (COVID-19), but there are safety concerns." | 1.56 | Effects of hydroxychloroquine treatment on QT interval. ( Adabag, S; Bart, B; Hooks, M; Vardeny, O; Westanmo, A, 2020) |
| "It may cause severe viral pneumonia with Acute Respiratory Distress Syndrome requiring critical care." | 1.56 | Very severe COVID-19 in the critically ill in Tunisia. ( Boussarsar, M; Ennouri, E; Jerbi, S; Mahmoud, J; Meddeb, K; Nachi, R; Saida, IB; Thabet, N, 2020) |
| "In 22 SLE patients with chronic renal insufficiency (median serum creatinine clearance 52 ml/minute [range 23-58 ml/minute]) who received 400 mg/day HCQ, the median blood HCQ concentration was significantly higher than that in the 509 patients from the PLUS study (1,338 ng/ml [range 504-2,229 ng/ml] versus 917 ng/ml [range 208-3316 ng/ml]) (P < 0." | 1.42 | Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. ( Ackermann, F; Amoura, Z; Asli, B; Aumaître, O; Blanchet, B; Cacoub, P; Cohen-Bittan, J; Costedoat-Chalumeau, N; Desmurs-Clavel, H; Fain, O; Francès, C; Galicier, L; Hulot, JS; Jallouli, M; Kahn, JE; Le Guern, V; Le Thi Huong, D; Leroux, G; Limal, N; Lioté, F; Mariette, X; Papo, T; Perard, L; Piette, JC; Pourrat, J; Sacré, K; Sailler, L; Sellam, J; Smail, A; Stirnemann, J; Zahr, N, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 13 (72.22) | 2.80 |
| Authors | Studies |
|---|---|
| Belmont, HM | 1 |
| Haj-Ali, M | 1 |
| Li, D | 1 |
| Yu, K | 1 |
| Feng, F | 1 |
| Zhang, Y | 2 |
| Bai, F | 1 |
| Sun, N | 1 |
| Fan, J | 1 |
| Liu, L | 1 |
| Yang, H | 1 |
| Yang, X | 1 |
| Enfrein, A | 1 |
| Pirson, V | 1 |
| Le Guern, V | 2 |
| Karras, A | 1 |
| Tamirou, F | 1 |
| Costedoat-Chalumeau, N | 2 |
| Houssiau, F | 1 |
| Muanda, FT | 1 |
| Blake, PG | 1 |
| Weir, MA | 1 |
| Ahmadi, F | 1 |
| McArthur, E | 1 |
| Sontrop, JM | 1 |
| Urquhart, BL | 1 |
| Kim, RB | 1 |
| Garg, AX | 1 |
| Fanouriakis, A | 1 |
| Bertsias, G | 1 |
| Boumpas, DT | 1 |
| Wu, CY | 1 |
| Tan, M | 1 |
| Huang, JY | 1 |
| Chiou, JY | 1 |
| Wei, JC | 1 |
| Melgosa, M | 1 |
| Madrid, A | 1 |
| Alvárez, O | 1 |
| Lumbreras, J | 1 |
| Nieto, F | 1 |
| Parada, E | 1 |
| Perez-Beltrán, V | 1 |
| Mattioli, M | 1 |
| Fustini, E | 1 |
| Gennarini, S | 1 |
| Hooks, M | 1 |
| Bart, B | 1 |
| Vardeny, O | 1 |
| Westanmo, A | 1 |
| Adabag, S | 1 |
| Patel, M | 1 |
| Gangemi, A | 1 |
| Marron, R | 1 |
| Chowdhury, J | 1 |
| Yousef, I | 1 |
| Zheng, M | 1 |
| Mills, N | 1 |
| Tragesser, L | 1 |
| Giurintano, J | 1 |
| Gupta, R | 1 |
| Gordon, M | 1 |
| Rali, P | 1 |
| D'Alonso, G | 1 |
| Fleece, D | 1 |
| Zhao, H | 1 |
| Patlakh, N | 1 |
| Criner, G | 1 |
| Saida, IB | 1 |
| Ennouri, E | 1 |
| Nachi, R | 1 |
| Meddeb, K | 1 |
| Mahmoud, J | 1 |
| Thabet, N | 1 |
| Jerbi, S | 1 |
| Boussarsar, M | 1 |
| Miller-Handley, H | 1 |
| Luckett, K | 1 |
| Govil, A | 1 |
| Shukla, AM | 2 |
| Segal, MS | 2 |
| Pepine, CJ | 1 |
| Cheung, AK | 1 |
| Shuster, J | 1 |
| Mohandas, R | 1 |
| Martinez, WM | 1 |
| Flint, JJ | 1 |
| Shah, SV | 2 |
| Wu, CL | 1 |
| Chang, CC | 1 |
| Kor, CT | 1 |
| Yang, TH | 1 |
| Chiu, PF | 1 |
| Tarng, DC | 1 |
| Hsu, CC | 1 |
| Rodrigues, JC | 1 |
| Bargman, JM | 1 |
| Pokroy-Shapira, E | 1 |
| Gelernter, I | 1 |
| Molad, Y | 1 |
| Jallouli, M | 1 |
| Galicier, L | 1 |
| Zahr, N | 1 |
| Aumaître, O | 1 |
| Francès, C | 1 |
| Lioté, F | 1 |
| Smail, A | 1 |
| Limal, N | 1 |
| Perard, L | 1 |
| Desmurs-Clavel, H | 1 |
| Le Thi Huong, D | 1 |
| Asli, B | 1 |
| Kahn, JE | 1 |
| Pourrat, J | 1 |
| Sailler, L | 1 |
| Ackermann, F | 1 |
| Papo, T | 1 |
| Sacré, K | 1 |
| Fain, O | 1 |
| Stirnemann, J | 1 |
| Cacoub, P | 1 |
| Leroux, G | 1 |
| Cohen-Bittan, J | 1 |
| Sellam, J | 1 |
| Mariette, X | 1 |
| Blanchet, B | 1 |
| Hulot, JS | 1 |
| Amoura, Z | 1 |
| Piette, JC | 1 |
| Bose, C | 1 |
| Karaduta, OK | 1 |
| Apostolov, EO | 1 |
| Kaushal, GP | 1 |
| Fahmi, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxychloroquine for the Management of CVD in CKD[NCT03636152] | Phase 2 | 100 participants (Anticipated) | Interventional | 2018-12-14 | Recruiting | ||
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
1 review available for hydroxychloroquine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanize | 2020 |
17 other studies available for hydroxychloroquine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Whole blood drug levels do not correlate with QTc intervals in hydroxychloroquine-treated systemic lupus erythematosus patients.
Topics: Antirheumatic Agents; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Humans; Hydroxychloroq | 2022 |
Hydroxychloroquine alleviates renal interstitial fibrosis by inhibiting the PI3K/Akt signaling pathway.
Topics: Animals; Epithelial-Mesenchymal Transition; Female; Fibrosis; Humans; Hydroxychloroquine; Kidney; Ma | 2022 |
Worse long-term renal outcome of lupus nephritis patients of African descent living in Europe.
Topics: Creatinine; Humans; Hydroxychloroquine; Kidney; Lupus Nephritis; Renal Insufficiency, Chronic; Retro | 2022 |
Low-Dose Methotrexate and Serious Adverse Events Among Older Adults With Chronic Kidney Disease.
Topics: Aged; Cohort Studies; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Ontario; Renal Dialysi | 2023 |
Response to: 'Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus' by Wu
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Renal Insufficiency, Chronic | 2022 |
Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lupus Nephritis; Renal Insufficiency, Chr | 2022 |
SARS-CoV-2 infection in Spanish children with chronic kidney pathologies.
Topics: Adolescent; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Coronavirus Infections; COVI | 2020 |
Heart transplant recipient patient with COVID-19 treated with tocilizumab.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Cardiomyopathy, Dilated; C | 2020 |
Effects of hydroxychloroquine treatment on QT interval.
Topics: Antirheumatic Agents; Atrial Fibrillation; Betacoronavirus; Coronavirus Infections; COVID-19; Drug M | 2020 |
Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antirheumat | 2020 |
Very severe COVID-19 in the critically ill in Tunisia.
Topics: Antiviral Agents; Betacoronavirus; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COV | 2020 |
Management of Cardiovascular Disease in Kidney Disease Study: Rationale and Design.
Topics: Cardiovascular Diseases; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic; Renal In | 2021 |
Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Incide | 2018 |
Antimalarial Drugs for the Prevention of Chronic Kidney Disease in Patients with Rheumatoid Arthritis: The Importance of Controlling Chronic Inflammation?
Topics: Antimalarials; Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Inflammation; Renal Insufficiency, | 2018 |
Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study.
Topics: Adolescent; Adult; Aged; Child; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hydro | 2014 |
Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Body Mass Index; Creatinine; Female; Humans; H | 2015 |
Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease.
Topics: Animals; Aorta; Atherosclerosis; Bilirubin; Blood Glucose; Elasticity; Hydroxychloroquine; Inflammat | 2015 |